Combined targeting of STAT 3 and STAT 5
Combined targeting of STAT 3 and STAT 5: a novel approach to overcome drug resistance in chronic myeloid leukemia by Karoline V. Gleixner, Mathias Schneeweiss, Gregor Eisenwort, Daniela Berger, Harald Herrmann, Katharina Blatt, Georg Greiner, Konstantin Byrgazov, Gregor Hoermann, Marina Konopleva, Islam Waliul, Abbarna A. Cumaraswamy, Patrick T. Gunning, Hiroshi Maeda, Richard Moriggl, Michael Deininger, Thomas Lion, Michael Andreeff, and Peter Valent haematol Volume 102(9): 1519 -1529 August 31, 2017 © 2017 by Ferrata Storti Foundation
Patients’ characteristics and response of leukemic cells to CDDO-Me. Karoline V. Gleixner et al. Haematologica 2017; 102: 15191529 © 2017 by Ferrata Storti Foundation
CDDO-Me inhibits growth and viability of Philadelphia-positive (Ph+) cell lines. Karoline V. Gleixner et al. Haematologica 2017; 102: 15191529 © 2017 by Ferrata Storti Foundation
CDDO-Me counteracts the proliferation of primary chronic myeloid leukemia (CML) cells. Karoline V. Gleixner et al. Haematologica 2017; 102: 15191529 © 2017 by Ferrata Storti Foundation
CDDO-Me synergizes with BCR-ABL 1 TKI in producing growth-inhibition in Philadelphia-positive (Ph+) cells. Karoline V. Gleixner et al. Haematologica 2017; 102: 15191529 © 2017 by Ferrata Storti Foundation
Combined inhibition of STAT 3 and STAT 5 with sh. RNA and targeted drugs results in synergistic growth inhibition in chronic myeloid leukemia (CML) cells. Karoline V. Gleixner et al. Haematologica 2017; 102: 15191529 © 2017 by Ferrata Storti Foundation
SMA-Zn. PP sensitizes BCR-ABL 1+ cells against CDDO-Me and against the combination “CDDOMe+BCR-ABL 1 TKI”. Karoline V. Gleixner et al. Haematologica 2017; 102: 15191529 © 2017 by Ferrata Storti Foundation
- Slides: 7